StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a report published on Tuesday. The brokerage issued a hold rating on the stock.
TherapeuticsMD Stock Up 1.8 %
NASDAQ TXMD opened at $2.29 on Tuesday. TherapeuticsMD has a twelve month low of $1.95 and a twelve month high of $4.72. The stock has a 50-day moving average of $2.32 and a 200 day moving average of $2.45.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in TherapeuticsMD by 727.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company’s stock worth $1,087,000 after purchasing an additional 2,514,618 shares in the last quarter. Renaissance Technologies LLC raised its stake in TherapeuticsMD by 243.5% in the first quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock valued at $1,196,000 after buying an additional 2,231,301 shares in the last quarter. Royal Bank of Canada raised its stake in TherapeuticsMD by 688.1% in the first quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock valued at $299,000 after buying an additional 688,399 shares in the last quarter. Tejara Capital Ltd acquired a new stake in TherapeuticsMD in the fourth quarter valued at $1,774,000. Finally, ADAR1 Capital Management LLC acquired a new stake in TherapeuticsMD in the fourth quarter valued at $612,000. 30.74% of the stock is currently owned by hedge funds and other institutional investors.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.
Further Reading
- Five stocks we like better than TherapeuticsMD
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How to Invest in Blue Chip Stocks
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 3 Best Fintech Stocks for a Portfolio Boost
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
